Ghatnekar, Ola, et al. “Cost-Effectiveness of Dasatinib Versus High-Dose Imatinib in Patients With Chronic Myeloid Leukemia (CML), Resistant to Standard Dose Imatinib – a Swedish Model Application”. Acta Oncologica, vol. 49, no. 6, Aug. 2010, pp. 851-8, doi:10.3109/0284186X.2010.495132.